Diagnosis and Japanese Guideline

  • Hidehisa SaekiEmail author


Based on the definition and diagnostic criteria for atopic dermatitis (AD) by the Japanese Dermatological Association (JDA), patients meeting three basic items – (1) pruritus, (2) typical morphology and distribution of the eczema, and (3) chronic or chronically relapsing course – are regarded as having AD. Eruption is symmetrically distributed and frequently develops on the forehead, periorbital area, perioral area, lips, periauricular area, neck, joint areas of limbs, and trunk. Its distribution is characterized by age. The clinical practice guidelines for the management of AD 2016 by the JDA were prepared as a regular revision for all children to adults with all severity of AD, involving internationally published novel findings on AD in 2016. Treatment measures for AD basically consist of drug therapy, skin care with emollients for physiological abnormalities in the skin, and investigations/elimination of exacerbating factors based on its pathogenesis. Drugs that potently reduce AD-related inflammation and of which the efficacy and safety have been scientifically examined include topical corticosteroids and tacrolimus. It is important to promptly and accurately reduce inflammation related to AD, and treatments are based on how topical corticosteroids and tacrolimus should be selected/combined for this purpose.


Atopic dermatitis Diagnostic criteria Japanese guideline Tacrolimus Topical corticosteroids 


  1. 1.
    Tagami H. Japanese Dermatological Association Criteria for the diagnosis of atopic dermatitis. J Dermatol. 1995;22:966–7.CrossRefGoogle Scholar
  2. 2.
    Saeki H, Furue M, Furukawa F, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009;36:563–77.CrossRefPubMedGoogle Scholar
  3. 3.
    Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Dermatol Venereol Suppl (Stockh). 1980;92:44–7.Google Scholar
  4. 4.
    Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49:1088–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Williams HC, Burney PGJ, Pembroke AC, et al. The UK Working Party’s Diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131:406–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Saeki H, Iizuka H, Mori Y, et al. Community validation of the U.K. diagnostic criteria for atopic dermatitis in Japanese elementary schoolchildren. J Dermatol Sci. 2007;47:227–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol. 1999;103:125–38.CrossRefPubMedGoogle Scholar
  8. 8.
    Nishima S, Odajima H. Prevalence of childhood allergic diseases in Japan using international study of asthma and allergies in childhood (ISAAC) phase I protocol. Jpn J Pediatr Allergy Clin Immunol. 2002;16:207–20. (in Japanese with English abstract)CrossRefGoogle Scholar
  9. 9.
    Aoki T. The second report from the Advisory Committee for Atopic Dermatitis Severity Classification. Jpn J Dermatol. 2001;111:2023–33. (in Japanese)Google Scholar
  10. 10.
    Yoshida H. Interim report from the Advisory Committee for Atopic Dermatitis Severity Classification. Jpn J Dermatol. 1998;108:1491–6. (in Japanese)Google Scholar
  11. 11.
    Katayama I, Kohno Y, Akiyama K, et al. Japanese guideline for atopic dermatitis 2014. Allergol Int. 2014;63:377–98.CrossRefGoogle Scholar
  12. 12.
    European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186:23–31.CrossRefGoogle Scholar
  13. 13.
    Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11–8.CrossRefGoogle Scholar
  14. 14.
    Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13–4.Google Scholar
  15. 15.
    Furue M, Ebata T, Ikoma A, et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol. 2013;93:214–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Chren MM, Lasek RJ, Sahay AP, et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105–10.CrossRefPubMedGoogle Scholar
  17. 17.
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Higaki Y, Kawamoto K, Kamo T, et al. The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol. 2002;29:693–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Takahashi N, Suzukamo Y, Nakamura M, et al. Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes. 2006;4:46.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol. 2016;43:1117–45.CrossRefPubMedGoogle Scholar
  21. 21.
    Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci. 2006;43:75–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Tamaki K, Saeki H, Kadono T, et al. Serum TARC⁄CCL17 levels as a disease marker of atopic dermatitis. Jpn J Dermatol. 2006;116:27–39. (In Japanese with English abstract)Google Scholar
  23. 23.
    Fujisawa T, Nagao M, Noma Y, et al. Clinical utility of serum TARC/CCL17 for monitoring clinical course of atopic dermatitis in children. Jpn J Pediatr Allergy Clin Immunol. 2005;19:744–57. (In Japanese with English abstract)CrossRefGoogle Scholar
  24. 24.
    Kawashima M, Takigawa M, Nakagawa H, et al. Guidelines for therapy for atopic dermatitis. Jpn J Dermatol. 2000;110:1099–104. (In Japanese with English abstract)Google Scholar
  25. 25.
    Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70:3–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exp Dermatol. 1991;16:444–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Yanai K, Zhang D, Tashiro M, et al. Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opin Drug Saf. 2011;10:613–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Murota H, Takahashi A, Nishioka M, et al. Showering reduces atopic dermatitis in elementary school students. Eur J Dermatol. 2010;20:410–1.PubMedGoogle Scholar
  31. 31.
    Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332:933–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of DermatologyNippon Medical SchoolTokyoJapan

Personalised recommendations